Best Practice Models for Opioid Treatment Programs Motivated Stepped Care: An Adaptive Treatment Approach. Van L. King, MD

Similar documents
Opioid Treatment Program Reimbursement Re-bundling Proposal

Trigger. Myths About the Use of Medication in Recovery BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

SW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass

The Importance of Psychological Treatment and Behavioral Support

Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction

Management Options for Opioid Dependence:

ROSC & MAT II: Opioid Treatment Services

Improving Outcomes in Methadone Treatment

2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders

The role of behavioral interventions in buprenorphine treatment of opioid use disorders

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

STARTING SUBOXONE IN PRIMARY CARE

7/7/2016 Journal of the American Medical Association,

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

DMHAS ASAM SERVICE DESCRIPTIONS

The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine. March 10, 2016

RI Centers of Excellence for the

Prescription Monitoring Program. One Agency s Experience. Ron Jackson, MSW, LICSW Evergreen Treatment Services Seattle, WA

Confronting the Opioid Epidemic: Suboxone in Primary Care

Behavioral Therapies for Methamphetamine Use

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC

THE UNSTABLE BUPRENORPHINE- NALOXONE PATIENT

Treatment of Methamphetamine Dependence: Does Treatment Work?

Vermont Hub and Spoke Model Treatment Need Questionnaire

Treatment of Youth Opioid Addiction: Approaches to a Modern Epidemic. What should we do with this case? Heroin Addiction History

POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE

The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

Medication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs

Appendix F Federation of State Medical Boards

Referral to Treatment: Utilizing the ASAM Criteria

6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder

Opioids Research to Practice

TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS

Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version

Initiation and engagement in addiction treatment integrated into primary care: the role of gender

Buprenorphine as a Treatment Option for Opioid Use Disorder

What Predicts the Successful Completion of Addiction Treatment?

Opioid Use Disorder Treatment Initiation in Diverse Settings

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center

EFFECTIVE PROGRAM PRINCIPLES MATRIX

CHAPTER 27: BEHAVIOR ANALYSIS AND TREATMENT OF DRUG ADDICTION

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer

Substance Abuse Suboxone Treatment

Identifying methadone maintenance clients at risk for poor treatment response: Pretreatment and early progress indicators

Clinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder

Vivitrol/Suboxone. Comparison Study Summary

Management of Opioid Use Disorder in Primary Care

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines

Optimizing Suboxone in Opioid Addicts

Evidence-Based Practice: Psychosocial Interventions

IntNSA Webinar Series

RECOMMENDATIONS FOR HEALTH CARE PROVIDERS

Opioid Treatment in North Carolina SEPTEMBER 13, 2016

Opioids Research to Practice

OPIOID USE DISORDER CENTERS OF EXCELLENCE APPLICATION GENERAL INFORMATION

Medicaid and the Opioid Crisis

Counseling plus Buprenorphine Naloxone Maintenance Therapy for Opioid Dependence

Serious Mental Illness and Opioid Use Disorder

Psychosocial Treatments for Opioid Use Disorder Overview

OPIOIDS: ENGAGING PATIENTS IN OUD TREATMENT

HEALTHWEST. Procedure. No Prepared by: Effective Date: April 5, 2018 Revised Date: December 11, 2018

Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone

An Adaptive Reinforcement-Based Treatment (RBT) Intervention for Pregnant Substance Dependent Women

Readopt with amendment Med 502, effective (Document #11090), to read as follows:

Project Connections Buprenorphine Program

Integrated Dual Disorders Treatment (IDDT) Fidelity Scale Tips and Tools Treatment Characteristics and Organizational Characteristics

Medication Assisted Treatment of Substance Use Disorders

ORGANIZATION OF AMERICAN STATES INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION RECOVERY-ORIENTED SYSTEMS OF CARE

Handbook for Postdoctoral Fellows at The Menninger Clinic

Triage, Assessment and Treatment Planning

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008

AMBULATORY DETOXIFICATION In the 21 st Century

NORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014

Medication-Assisted Treatment (MAT) Overview

Vivitrol Drug Court and Medication Assisted Treatment

Effective Treatment: Doing the Right Thing, In the Right Way. Terrence D Walton, MSW, ICADC

Understanding and Combating the Heroin Epidemic

Addiction and Recovery Treatment Services (ARTS) Reimbursement Structure

Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence(review)

Handbook for Postdoctoral Fellows at The Menninger Clinic

Youth, Opioid Use and Treatment Options. CPSO MMT Providers Conference Dr. Sharon Cirone MD FCFPC November 2016

The percentage of individuals admitted

Hospitals Role in Addressing the Opioid Crisis

MGH Substance Use Disorder Initiative. Dawn Williamson, RN, DNP, PMHCNS-BC, CARN-AP MGH ED Christopher Shaw, RN, ANP, PMHNP-BC, CARN-AP MGH ACT

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

Medication Assisted Treatment. Nicole Gastala, MD

Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients

The Opioid Crisis: What Can Physicians Do About It?

Building capacity for a CHC response to Ontario's Opioid Crisis

Note: The trainings below represent a foundational list, and may be adapted based on audience and need.

HEALTHWEST. Procedure. No Prepared by: Effective Date: June 1, 2017 Revised Date: November 13, 2018 Cyndi Blair, RNBC Chief Clinical Officer

Vivitrol Vs. Suboxone

BASIC VOLUME. Elements of Drug Dependence Treatment

NIDA Principles of Treatment. NIDA Principles of Treatment. Peter Banys, M.D., M.Sc. No single treatment is appropriate for all individuals.

OUTPATIENT TREATMENT WESTPORT, CONNECTICUT

Note: The trainings below represent a foundational list, and may be adapted based on audience and need.

John Murphy DO, MS Lynx Healthcare

Transcription:

Best Practice Models for Opioid Treatment Programs Motivated Stepped Care: An Adaptive Treatment Approach Van L. King, MD UT Health, Department of Psychiatry Grand Rounds November 15, 2016

Addiction Treatment Services Hospital-based clinic established 1972 in southeast Baltimore Comprehensive drug abuse treatment using methadone as one component of care Census of 500 primarily opioid dependent patients typical of patients in similar community-based treatment programs Long term or indefinite length of treatment

Common Problems Poor adherence to treatment services Partial and poor treatment response Fixed and limited levels of service Reliance on single elements of care Staff and patient demoralization

Solution Improve treatment adherence Use combination of evidence-based approaches Efficient use of resources using a patient - treatment matching paradigm Expose more symptomatic patients to most experienced and trained staff

Definition of Adaptive Treatment Strategy Use evidence-based treatment guidelines use empirically-based interventions integrate and combine interventions match intensity/dose of service to symptom severity Use established rules to guide treatment planning initiation of treatment services changes in intensity and type of services discharge and return to treatment Use interventions to achieve good patient adherence motivational interventions behavioral incentives available social supports

Recognize Importance of Opioid Agonist Medications One of the most effective interventions for opioid dependence (Hazelton now endorses) Use flexible dispensing schedules and doses Integrate with other interventions to improve response Ball and Ross, 1991 McLellan et al., 1993

Recognize Importance of Psychotherapies Intensifying routine drug abuse counseling can reduce drug use Adding professional psychotherapies can further reduce drug use Woody et al., 1983, 1995 McLellan et al., 1993 Kidorf et al., 1999 Brooner et al., 2004

Recognize Importance of Behavioral Reinforcement Effective behavioral incentives will enhance reductions in drug use Kidorf et al., 1993,1999 Silverman et al., 1996 Rawson et al., 2002 Brooner et al., 2004, 2007 King & Brooner, 2007 Effective behavioral incentives will enhance attendance to counseling sessions Stitzer et al., 1977 Kidorf et al., 1994,1999 Brooner et al., 2004, 2007

Use Behavioral Reinforcement to Improve Treatment Adherence Methadone dosing time restrictions Methadone dose taper in preparation for discharge Rapid methadone taper reversal and/ or clinic re-admission for treatment adherence

Motivated Stepped Care Adaptive Treatment Model Use evidence-based treatment guidelines opioid agonist treatment cognitive behavioral therapy / motivational interventions behavioral reinforcement Use established rules to guide treatment planning adaptive stepped care treatment matching utilizing ongoing treatment outcome data step rules followed by all staff and for all patients Use interventions to achieve good adherence fully integrate evidence-based treatments supervisors and doctors lead intensified group treatment use available social supports

Addiction Treatment Services Program Overview New Admissions Admission Evaluation History/Physical Admit Lab Work Infectious Diseases Other Evaluation Psychiatric Other Substance Use Psychosocial Treatment Services - On Site Medications Limited Medical Care Weekly Urine Testing Counseling Weeks 1-4 Treatment Induction and Initial Stabilization Begin Motivated Stepped Care System Week 5

Bi-directional Motivated Stepped Care (MSC) Model Medical Maintenance Schedules 13 take-home medication doses 27 take-home medication doses indefinite duration STEP 1 1 individual session wk/mo indefinite duration STEP 2 1 individual session/week 2 group sessions/week 2-4 weeks STEP 3 1-2 individual sessions/week 8 group sessions/week 4-8 weeks Methadone Taper and Discharge 30-day taper to zero dose reverse taper for 1 week attendance guaranteed readmission in 24 hours

Motivated Stepped Care (MSC) in Action STEP 1 1 individual session wk/mo indefinite duration STEP 2 1 individual session/week 2 group sessions/week 2-4 weeks Patients move from Step 1 to Step 2 after 2 consecutive weeks of: missed counseling sessions AND/OR drug positive urine specimens

Motivated Stepped Care (MSC) in Action STEP 1 1 individual session wk/mo indefinite duration STEP 2 1 individual session/week 2 group sessions/week 2-4 weeks Patients move from Step 2 back to Step 1 if during the 4 week period they: attend all counseling for 2 consecutive weeks AND are drug negative for 2 consecutive weeks

Motivated Stepped Care (MSC) in Action STEP 2 1 individual session/week 2 group sessions/week 2-4 weeks STEP 3 1 individual session/week 8 group sessions/week 4-8 weeks Patients move from Step 2 to Step 3 if during the 4 week period they produce 2 weeks of: missed counseling sessions AND/OR drug positive urine specimens

Motivated Stepped Care (MSC) in Action STEP 1 1 individual session wk/mo indefinite duration STEP 3 1 individual session/week 8 group sessions/week 4-8 weeks Patients move back from Step 3 to Step 1 if during the 8 week period they: attend all counseling sessions in 4 consecutive weeks AND have drug negative urines in 4 consecutive weeks

Motivated Stepped Care (MSC) in Action STEP 3 1 individual session/week 8 group sessions/week 4-8 weeks Patients move from Step 3 to a medication taper and possible discharge if they do not produce over 8 weeks: Methadone Taper and Discharge 30-day taper to zero dose reverse taper for 1 week adherence guaranteed readmission in 24 hours 4 consecutive weeks of full counseling attendance AND 4 consecutive weeks of drug negative urine specimens

Motivated Stepped Care (MSC) in Action Medication taper reversed and restart Step 3 by: attending all counseling for 1 week AND submitting single drug negative urine STEP 3 1 individual session/week 8 group sessions/week 4-8 weeks Methadone Taper and Discharge 30-day taper to zero dose reverse taper for 1 week adherence guaranteed readmission in 24-hours

Motivated Stepped Care (MSC) in Action STEP 3 1 individual sessions/week 8 group sessions/week 4-8 weeks Readmission after taper in 1 to 7 days with agreement to: restart care in Step 3 AND work towards Step 1 Methadone Taper and Discharge 30-day taper to zero dose reverse taper for 1 week adherence guaranteed rapid readmission

Randomized and Controlled Clinical Trial Enrolled new admissions (n=144/160) Methadone induction. Completed 1 month baseline (n=127) Motivated Stepped Care (MSC) Randomized to: -or- Standard Stepped Care (SSC) STEP 1 (New Admits) N=65 STEP 1 (New Admits) N=62 STEP 2 (2-4 Weeks) STEP 2 (2-4 Weeks) STEP 3 (4-8 Weeks) Discharge STEP 3 (4-8 Weeks) Discharge Rapid Readmission Rapid Readmission Participants compared on: 90 day retention, counseling adherence/attendance, weekly drug positive urine

Demographic Characteristics of Sample Variable MSC SSC p Age (yrs) 38.0 38.4 ns Education (yrs) 11.1 11.7 ns Female 57% 52% ns Minority 60% 66% ns

% Completing 90 Days Randomized Care Treatment Retention

Weekly Counseling Adherence % Sessions Attended * * MSC SSC

Weekly Urinalysis Results % Positive Urine Samples * MSC SSC

Post-Trial Therapeutic Transfer of Controls Rescue of poor responders Pre-defined partial/poor responding Transfer to MSC treatment (35/62 = 60%) Within-subject crossover design

Counseling Adherence: Pre & Post Transfer (n=35) % Sessions Attended * Pre-90 days Post-90 days *

Urinalysis Results: Pre & Post Transfer (n=35) % Positive Urine Samples * Pre-90 days Post-90 days *

MSC is Powerful and Versatile Reduces cannabis use Kidorf et al., 2007 Improves involvement of family and other community supports Kidorf et al., 1997; 2007 Improves rates of employment and other productive activity Kidorf et al., 1998; 2004 As effective as voucher based protocols in decreasing drug use Brooner et al., 2007

Conclusions/Summary Single service and restricted care models are not adequate to treat the range of needs Severe, long-term problems benefit from adaptive, long-term treatment solutions MSC is an efficient and clinically effective approach to match the amount of treatment to objective ongoing indicators of symptom severity and treatment response

Be Well Clinic, UT Health Structured, multiple levels of service intensity. Can accommodate short-term and long-term treatment needs. Behaviorally integrate medication and counseling services. Utilize buprenorphine or naltrexone for opioid use. Utilize naltrexone and other medications for other drug use disorders. Utilize other reinforcers such as family, social support and legal status to assist in process of rehabilitation and recovery.

Thank you 4 3 2 1

Continuous Performance Improvement Collection and tracking of counseling attendance and urine testing data using a computer-based platform All data monitored weekly by executive staff Data monitored weekly in clinical rounds for Step 3 patients Data monitored monthly/ quarterly for reduced care patients